Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 1.00 |
| ▸ | GAA | P10253 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | APAF1 | O14727 | 2/20 | 0.71 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.71 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | PKM | P14618 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26115021 | 0.89 | MAPT (0.80) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL31653615 | 0.89 | MAPT (0.80) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL26135108 | 0.89 | MAPT (0.80) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL26116760 | 0.71 | SMN1; SMN2 (0.61) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL26134827 | 0.71 | SMN1; SMN2 (0.61) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL26135075 | 0.71 | SMN1; SMN2 (0.61) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL3813156 | 0.71 | MAPT (0.66) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL7689352 | 0.70 | MAPT (0.78) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL17903202 | 0.69 | KMT2A (0.70) | MAPTGAAKDM4EALDH1A1POLB | |
| SCHEMBL11961916 | 0.68 | MAPT (0.79) | MAPTGAAKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053977-A1 | Medicinal uses of hydrazones | ALMSTEAD JI-IN KIM (US) | 2004-03-18 | — | — | US | claimed |
| US-6660737-B2 | Antihypoxic agents | THE PROCTER & GAMBLE COMPANY | 2003-12-09 | — | — | US | claimed |
| US-20030092716-A1 | Medicinal uses of hydrazones | THE PROCTER & GAMBLE COMPANY | 2003-05-15 | — | — | US | claimed |
| US-20040053977-A1 | Medicinal uses of hydrazones | ALMSTEAD JI-IN KIM (US) | 2004-03-18 | — | — | US | disclosed |
| US-6660737-B2 | Antihypoxic agents | THE PROCTER & GAMBLE COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-20030092716-A1 | Medicinal uses of hydrazones | THE PROCTER & GAMBLE COMPANY | 2003-05-15 | — | — | US | disclosed |
| WO-2002089809-A1 | MEDICINAL USES OF HYDRAZONES AND HYDRAZINES | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053977-A1 | Medicinal uses of hydrazones | PGF, VEGFA, TEK | MAPT 4168/4885GAA 1089/4885KDM4E 4483/4885 |
| US-20030092716-A1 | Medicinal uses of hydrazones | EPOR, VEGFA, HIF1A | MAPT 4120/4885GAA 635/4885KDM4E 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.